Source:http://linkedlifedata.com/resource/pubmed/id/16374426
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2005-12-23
|
pubmed:abstractText |
Diabetic nephropathy involves a renal inflammatory response induced by the diabetic milieu. Macrophages accumulate in diabetic kidneys in association with the local upregulation of monocyte chemoattractant protein-1 (MCP-1); however, the contribution of macrophages to renal injury and the importance of MCP-1 to their accrual are unclear. Therefore, we examined the progression of streptozotocin (STZ)-induced diabetic nephropathy in mice deficient in MCP-1 in order to explore the role of MCP-1-mediated macrophage accumulation in the development of diabetic kidney damage. Renal pathology was examined at 2, 8, 12 and 18 weeks after STZ treatment in MCP-1 intact (+/+) and deficient (-/-) mice with equivalent blood glucose and hemoglobin A1c levels. In MCP-1(+/+) mice, the development of diabetic nephropathy was associated with increased kidney MCP-1 production, which occurred mostly in tubules, consistent with our in vitro finding that elements of the diabetic milieu (high glucose and advanced glycation end products) directly stimulate tubular MCP-1 secretion. Diabetes of 18 weeks resulted in albuminuria and elevated plasma creatinine in MCP-1(+/+) mice, but these aspects of renal injury were largely suppressed in MCP-1(-/-) mice. Protection from nephropathy in diabetic MCP-1(-/-) mice was associated with marked reductions in glomerular and interstitial macrophage accumulation, histological damage and renal fibrosis. Diabetic MCP-1(-/-) mice also had a smaller proportion of kidney macrophages expressing markers of activation (inducible nitric oxide synthase or sialoadhesin) compared to diabetic MCP-1(+/+) mice. In conclusion, our study demonstrates that MCP-1-mediated macrophage accumulation and activation plays a critical role in the development of STZ-induced mouse diabetic nephropathy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0085-2538
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
69
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
73-80
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16374426-Animals,
pubmed-meshheading:16374426-Chemokine CCL2,
pubmed-meshheading:16374426-Diabetes Mellitus, Experimental,
pubmed-meshheading:16374426-Diabetic Nephropathies,
pubmed-meshheading:16374426-Kidney,
pubmed-meshheading:16374426-Macrophage Activation,
pubmed-meshheading:16374426-Male,
pubmed-meshheading:16374426-Mice,
pubmed-meshheading:16374426-Mice, Inbred C57BL,
pubmed-meshheading:16374426-Streptozocin
|
pubmed:year |
2006
|
pubmed:articleTitle |
Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice.
|
pubmed:affiliation |
Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|